Investigational drug · Phase 2
SKLB1028
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Newly Diagnosed Acute Myeloid Leukemia (AML).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 6, 2022 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "SKLB1028"
First trial start
2021
Aug 31, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKLB1028", any sponsor or status.
Conditions studied
As listed on its trial records.
- Newly Diagnosed Acute Myeloid Leukemia (AML)
Approved drugs for the same conditions: Acute myeloid leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "SKLB1028" as an intervention, largest first.
- A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-MutatedPivotal-lookingStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT04716114 · 315 participants (planned) · Start Mar 24, 2021 · Primary completion Dec 2025
Drug: SKLB1028; Salvage Chemotherapy · For: Acute Myeloid Leukemia (AML)
Sites: Chengdu, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05072522 · 98 participants (planned) · Start Oct 2021 · Primary completion Oct 2023
Drug: SKLB1028 · For: Advanced Solid Tumors
Sites: Zhengzhou, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05445154 · 58 participants (planned) · Start Aug 31, 2021 · Primary completion Oct 31, 2024
Drug: SKLB1028 Dose Escalation · For: Newly Diagnosed Acute Myeloid Leukemia (AML)
Sites: Chengdu, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05069870 · 42 participants · Start Jun 7, 2021 · Primary completion Nov 2021
Drug: SKLB1028; Itraconazole and 2 more · For: Healthy Subjects
Sites: Beijing, China
- A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML PatientsStatus unknown
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT04015024 · 30 participants (planned) · Start Jul 2019 · Primary completion Apr 2021
Drug: SKLB1028 150mg bid; SKLB1028 200mg bid and 1 more · For: Acute Myeloid Leukemia
Sites: Chengdu, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05109663 · 26 participants · Start Apr 14, 2021 · Primary completion Jun 30, 2021
Drug: SKLB1028 · For: Healthy Subjects
Sites: Beijing, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT02859948 · 18 participants (planned) · Start May 2016 · Primary completion Dec 2017
Drug: SKLB1028 · For: Acute Myeloid Leukemia
Sites: Chengdu, China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05070195 · 14 participants · Start Jun 7, 2021 · Primary completion Jul 9, 2021
Drug: SKLB1028; Midazolam · For: Healthy Subjects
Sites: Beijing, China
- A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male SubjectsCompleted
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT05369858 · 6 participants · Start Aug 6, 2021 · Primary completion Sep 4, 2021
Drug: [14C] SKLB1028 · For: Healthy Male Subjects
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of drug-drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects.
Chen J, Wu J, Guo N, et al. · Clin Transl Sci 2024
- SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.
Cao ZX, Liu JJ, Zheng RL, et al. · Leukemia 2012
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.